Price
CHART BY
Frequently asked questions
What is Structure Therapeutics ADR's market capitalization?
The market capitalization of Structure Therapeutics ADR is $4.07B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Structure Therapeutics ADR?
Structure Therapeutics ADR's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$3.652. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Structure Therapeutics ADR's stock?
Currently, 14 analysts cover Structure Therapeutics ADR's stock, with a consensus target price of $99.77. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for Structure Therapeutics ADR?
Structure Therapeutics ADR's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$243.48M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Structure Therapeutics ADR?
Structure Therapeutics ADR has a free cash flow of -$196.67M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Structure Therapeutics ADR have, and what sector and industry does it belong to?
Structure Therapeutics ADR employs approximately 163 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Structure Therapeutics ADR's shares?
The free float of Structure Therapeutics ADR is 59.31M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $4.07B
- EPS (TTM)
- -$3.652
- Free Float
- 59.31M
- EBITDA (TTM)
- -$243.48M
- Free Cashflow (TTM)
- -$196.67M
Pricing
- 52W span
- $13.27$94.90
Analyst Ratings
The price target is $99.77 and the stock is covered by 14 analysts.
Buy
14
Hold
0
Sell
0
Information
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.
- Employees
- 163
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- GPCR
Fundamentals & EOD data from FactSet